Protagenic Therapeutics Statistics
Total Valuation
PTIX has a market cap or net worth of $3.70 million. The enterprise value is $2.83 million.
Important Dates
The last earnings date was Tuesday, May 13, 2025.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PTIX has 537,548 shares outstanding. The number of shares has increased by 28.54% in one year.
| Current Share Class | 537,548 |
| Shares Outstanding | 537,548 |
| Shares Change (YoY) | +28.54% |
| Shares Change (QoQ) | +18.30% |
| Owned by Insiders (%) | 18.11% |
| Owned by Institutions (%) | 7.68% |
| Float | 440,197 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.86
| Current Ratio | 0.86 |
| Quick Ratio | 0.81 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -512.79% and return on invested capital (ROIC) is -330.87%.
| Return on Equity (ROE) | -512.79% |
| Return on Assets (ROA) | -189.60% |
| Return on Invested Capital (ROIC) | -330.87% |
| Return on Capital Employed (ROCE) | 6,125.62% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.75M |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.24% in the last 52 weeks. The beta is 0.29, so PTIX's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -67.24% |
| 50-Day Moving Average | 3.76 |
| 200-Day Moving Average | 6.68 |
| Relative Strength Index (RSI) | 59.96 |
| Average Volume (20 Days) | 5,296,453 |
Short Selling Information
The latest short interest is 237,009, so 44.09% of the outstanding shares have been sold short.
| Short Interest | 237,009 |
| Short Previous Month | 295,428 |
| Short % of Shares Out | 44.09% |
| Short % of Float | 53.84% |
| Short Ratio (days to cover) | 0.02 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.41M |
| Pretax Income | n/a |
| Net Income | -5.24M |
| EBITDA | -5.36M |
| EBIT | -5.41M |
| Earnings Per Share (EPS) | -$13.05 |
Full Income StatementBalance Sheet
The company has $872,960 in cash and n/a in debt, giving a net cash position of $872,960 or $1.62 per share.
| Cash & Cash Equivalents | 872,960 |
| Total Debt | n/a |
| Net Cash | 872,960 |
| Net Cash Per Share | $1.62 |
| Equity (Book Value) | -88,329 |
| Book Value Per Share | -0.16 |
| Working Capital | -148,803 |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.63M |
| Capital Expenditures | n/a |
| Free Cash Flow | -3.63M |
| FCF Per Share | -$6.74 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |